Valturna is owned by Novartis.
Valturna contains Aliskiren Hemifumarate; Valsartan.
Valturna has a total of 1 drug patent out of which 0 drug patents have expired.
Valturna was authorised for market use on 16 September, 2009.
Valturna is available in tablet;oral dosage forms.
The generics of Valturna are possible to be released after 03 July, 2026.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8168616||NOVARTIS||Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension|| |
(3 years from now)
Market Authorisation Date: 16 September, 2009
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic